血管生成素在造血系统恶性肿瘤中的作用及机制（英文）

促血管生成因子不仅参与实体肿瘤的发生和进展,而且与非实体瘤(如白血病等)的发生和发展进程密切相关.在众多促血管生成因子中,血管生成素(angiogenin,ANG)可以促进实体瘤细胞的生长和血管生成,然而其引起血管生成异常的详细机制目前还不完全清楚.本文就近年来在非实体瘤中血管生成素的功能及其潜在的治疗作用的研究进展进行综述.     

血管生成素的结构与功能的研究进展

血管生成素(angiogenin,ANG)是一种有效的血管生成因子,是RNase超家族中惟一具有促血管生成能力的成员,也是目前已知的所有血管生成因子中独具核糖核酸酶活性的因子。ANG具有3个功能元件,即RNase活性中心、细胞表面结合位点及核定位序列。ANG参与血管生成的各个阶段,是其他血管生成因子诱导新血管生成的枢纽,其作用受到受体调节。在肿瘤的发生、发展及恶化过程中,ANG也具有非常重要的作用。通过对ANG促血管生成及细胞增殖机制的研究,为治疗肿瘤提供了多种靶点和途径。     

肿瘤血管生成抑制因子在实体瘤治疗中的应用

肿瘤的治疗是近年来广大科研及医务工作者共同关注的问题。本文通过对血管生成与肿瘤生长的关系、血管生成因子和血管生成抑制因子功能的阐述,说明了血管生成抑制因子在肿瘤发生过程中的可能作用,从而为实体瘤的抗血管生成疗法提供了理论依据。     

神经节苷脂GD3与肿瘤的血管生成作用(英文)

 血管生成作用 (angiogenesis)是实体瘤 (solidtumor)生长和扩散的必要条件 .实体瘤的微血管密度与肿瘤的恶性程度成正相关 ,而且也与病人的预后密切相关 .因此 ,对抗血管生成作用是一种很有吸引力的肿瘤疗法 .神经节苷脂GD3在多种类型的肿瘤中超常表达 .一般认为 ,神经节苷脂GD3有增强肿瘤本身及邻近组织中的血管生成作用 ,从而促进肿瘤的演进和转移 .最近的研究工作为这一假设提供了有力的实验证据 .应用GD3合酶的反意DNA转染肿瘤细胞从而抑制细胞中的GD3合酶的表达 ,极大地降低了细胞的内源GD3含量 .进一步的研究证明 ,抑制肿瘤细胞的GD3合成明显地降低了该肿瘤细胞的血管内皮生长因子 (VEGF)的水平 ,并使血管生成作用降至最小限度 .这些实验说明GD3在肿瘤的血管生成中具有重要的作用 .此外 ,GD3作为肿瘤的一种相关抗原 ,它与血管生成因子的协同效应将在未来的联合基因疗法中起到重要的作用     

微核糖核酸在肿瘤血管生成中的调节作用

微核糖核酸(microRNAs,miRNAs)是广泛存在于真核生物中的一类短小的、不编码蛋白质的RNA家族,由18-25个核苷酸组成的单链RNA。研究表明microRNAs对肿瘤的发生发展具有重要的调节作用。肿瘤血管生成是实体瘤侵袭转移的关键步骤,抗肿瘤血管生成的治疗已成为当前研究的焦点,已有研究表明,microRNAs参与肿瘤血管生成的调节作用,通过对肿瘤血管生成相关因子的调控,影响肿瘤生成。     

靶向调控血管生成素miRNA的筛选和验证

血管生成素是一个重要的促血管生成因子,在细胞增殖、迁移和凋亡等过程中均发挥重要作用,但其具体的分子机制尚待阐明.miRNA是一类长约22 nt的小RNA,在转录后水平调控基因的表达,广泛参与各种生物学过程.本文探索了可直接调控血管生成素表达的miRNA,希望为阐明血管生成素的作用机制提供线索.首先,我们利用数据库预测得到8个可能靶向结合血管生成素mRNA 3′端非编码区的miRNA;然后,用实验方法验证它们与血管生成素的靶向关系,发现miR-1208、miR-196b、miR-296、miR-409-3p、miR-570和miR-641这6个miRNA可以不同程度地抑制血管生成素的mRNA和蛋白质表达水平,但只有miR-196b、miR-296、miR-409-3p和miR-641可以直接结合血管生成素mRNA的3′端非编码区;进而,在血管内皮细胞中分别过表达这4个miRNA,发现miR-196b、miR-409-3p和miR-641可以抑制血管内皮细胞的细胞增殖,而miR-196b、miR-296和miR-409-3p可以抑制血管内皮细胞的管腔形成.以上结果表明,细胞内有多个miRNA调控血管生成素的表达,它们可能协调调节血管生成,抑或在血管生成的不同阶段发挥作用.我们的工作还为“一种mRNA可被多种microRNA调节,而一种microRNA可调节多种mRNA”假说提供了部分证据.     

血管生长素与治疗性血管生成的研究进展

血管生长素(angiogenin,ANG) 是一种分泌性的单链碱性蛋白质,由123个氨基酸组成,分子量为14.4kD,广泛分布在人体中.ANG属于核糖核酸酶超家族中的一员,具有低核糖核酸酶活性.研究证实,ANG是一种有效的促血管生成因子,参与血管生成的各个阶段,是其它血管生成因子诱导新血管生成的枢纽,在缺血性疾病的治疗方面显示出巨大的潜能.本文对ANG在治疗性血管生成方面的研究进展作一综述.     

靶向肿瘤血管生成的天然产物研究进展

血管生成在肿瘤的发生发展过程中起着非常重要的作用.促血管生成因子及其受体可以通过调节血管生成促进肿瘤发生发展.因此,发现和开发靶向血管生成因子药物已经成为治疗肿瘤的重要策略.近年来,天然产物因其结构多样、毒副作用低及作用机制独特等优势已然成为开发抗肿瘤药物的主要来源.本文归纳阐述了近年来靶向血管生成因子具有抗肿瘤活性的...     

四跨膜超家族蛋白CD151促血管生成的研究进展

利用促血管生成因子促进血管生成已成为当前治疗缺血性疾病研究的一个热点。CD151蛋白作为四跨膜超家族蛋白(transmembrane-4 superfamily proteins,TM4SF)的重要成员之一,其在促血管生成方面起着重要的作用。CD151在体外能促进血管内皮细胞的增值、迁移及管状结构的形成,在体内能增加大鼠缺血后肢和缺血心肌区域的微血管数量,促进血管生成。CD151蛋白作为一个新的促血管生成因子日益受到大家的关注。本文就CD151促血管生成的研究进展进行综述。     

微核糖核酸在肿瘤血管生成中的调节作用

微核糖核酸（microRNAs,miRNAs）是广泛存在于真核生物中的一类短小的、不编码蛋白质的RNA家族,由18-25个核苷酸组成的单链RNA。研究表明microRNAs对肿瘤的发生发展具有重要的调节作用。肿瘤血管生成是实体瘤侵袭转移的关键步骤,抗肿瘤血管生成的治疗已成为当前研究的焦点,已有研究表明,microRNAs参与肿瘤血管生成的调节作用,通过对肿瘤血管生成相关因子的调控,影响肿瘤生成。     

Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder

Angiogenesis is essential for tumor growth and progression and is mediated by positive and negative regulators of vessel growth. Since angiogenic mediators found in patient serum have been postulated to reflect the angiogenic potential of a malignant tumor, we investigated the angiogenic activity in the serum of patients with transitional cell carcinoma (TCC). The data were correlated to tumor characteristics and the clinical course of the patients. Eighty-one patients with transitional cell carcinoma and 53 control persons were included in the study. Preoperative serum samples were collected and both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were quantified by ELISA. Additionally, the serum evoked proliferative activity on human umbilical vein endothelial cells (HUVEC) was evaluated. Data were compared to the clinical course of the patients. Serum of tumor patients significantly enhanced the proliferative capacity of HUVEC, compared to cells grown in standard culture medium (p = 0.0032), but not when compared to serum from control persons. Serum from patients with superficial TCC and well differentiated tumors induced a significantly higher angiogenic response (ANG(hi)) than serum from patients with poorly differentiated and invasive carcinomas (ANG(lo); p = 0.037). VEGF level of ANG(hi) serum was 384.22 +/- 247.76 pg/ml (n = 37) which significantly differed from mean VEGF level detected in ANG(lo) serum (247.72 +/- 211.93 pg/ml, n = 42; p = 0.019). Similarly, mean bFGF levels were 9.58 +/- 5.91 pg/ml in ANG(hi) serum versus 5.74 +/- 3.52 pg/ml) in ANG(lo) serum (p = 0.0043). A negative correlation was established between VEGF/bFGF serum concentration and patient prognosis. The experiments demonstrate a positive correlation between VEGF and bFGF serum level and endothelial proliferation in vitro. The inverse relationship between angiogenic activity and tumor stage might disclose information about angiogenesis and tumor progression in TCC.     

Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro

Reciprocal growth factor exchange between endothelial and malignant cells within the tumor microenvironment may directly stimulate neovascularization; however, the role of host vasculature in regulating tumor cell activity is not well understood. While previous studies have examined the angiogenic response of endothelial cells to tumor-secreted factors, few have explored tumor response to endothelial cells. Using an in vitro co-culture system, we investigated the influence of endothelial cells on the angiogenic phenotype of breast cancer cells. Specifically, VEGF, ANG1, and ANG2 gene and protein expression were assessed. When co-cultured with microvascular endothelial cells (HMEC-1), breast cancer cells (MDA-MB-231) significantly increased expression of ANG2 mRNA (20-fold relative to MDA-MB-231 monoculture). Moreover, MDA-MB-231/HMEC-1 co-cultures produced significantly increased levels of ANG2 (up to 580 pg/ml) and VEGF protein (up to 38,400 pg/ml) while ANG1 protein expression was decreased relative to MDA-MB-231 monocultures. Thus, the ratio of ANG1:ANG2 protein, a critical indicator of neovascularization, shifted in favor of ANG2, a phenomenon known to correlate with vessel destabilization and sprouting in vivo. This angiogenic response was not observed in nonmalignant breast epithelial cells (MCF-10A), where absolute protein levels of MCF-10A/HMEC-1 co-cultures were an order of magnitude less than that of the MDA-MB-231/HMEC-1 co-cultures. Results were further verified with a functional angiogenesis assay demonstrating well-defined microvascular endothelial cell (TIME) tube formation when cultured in media collected from MDA-MB-231/HMEC-1 co-cultures. This study demonstrates that the angiogenic activity of malignant mammary epithelial cells is significantly enhanced by the presence of endothelial cells.     

Endothelial cell survival and apoptosis in the tumor vasculature

Angiogenesis is essential for the growth and metastasis of solid tumors. The balance of endothelial cell (EC) proliferation and apoptosis is a major determinant in tumor angiogenesis. Recently, several studies demonstrated that numerous angiogenic factors not only induce angiogenesis but also function as EC survival factors. Vascular endothelial growth factor (VEGF), a potent angiogenic factor, is also an EC survival factor in embryonic vasculogenesis and tumor angiogenesis. VEGF activates specific intracellular survival pathways in ECs including Bcl-2, A1, IAP, Akt, and Erk. Integrins may function as EC survival factors by preventing anoikis by enhancing binding to the extracellular matrix. In addition, integrins may function in concert with VEGF to promote EC survival. Angiopoietin-1 (Ang-1) has recently been shown to stabilize EC networks by binding to the EC-specific tyrosine kinase receptor Tie-2. Pericytes also function as EC survival factors, by cell-cell contact, secretion of survival factors, or both. Targeting any of the above mechanisms for EC survival may provide novel antineoplastic strategies.     

Flow shear stress regulates endothelial barrier function and expression of angiogenic factors in a 3D microfluidic tumor vascular model

Endothelial cells lining blood vessels are exposed to various hemodynamic forces associated with blood flow. These include fluid shear, the tangential force derived from the friction of blood flowing across the luminal cell surface, tensile stress due to deformation of the vessel wall by transvascular flow, and normal stress caused by the hydrodynamic pressure differential across the vessel wall. While it is well known that these fluid forces induce changes in endothelial morphology, cytoskeletal remodeling, and altered gene expression, the effect of flow on endothelial organization within the context of the tumor microenvironment is largely unknown. Using a previously established microfluidic tumor vascular model, the objective of this study was to investigate the effect of normal (4 dyn/cm²), low (1 dyn/cm²), and high (10 dyn/cm²) microvascular wall shear stress (WSS) on tumor-endothelial paracrine signaling associated with angiogenesis. It is hypothesized that high WSS will alter the endothelial phenotype such that vascular permeability and tumor-expressed angiogenic factors are reduced. Results demonstrate that endothelial permeability decreases as a function of increasing WSS, while co-culture with tumor cells increases permeability relative to mono-cultures. This response is likely due to shear stress-mediated endothelial cell alignment and tumor-VEGF-induced permeability. In addition, gene expression analysis revealed that high WSS (10 dyn/cm²) significantly down-regulates tumor-expressed MMP9, HIF1, VEGFA, ANG1, and ANG2, all of which are important factors implicated in tumor angiogenesis. This result was not observed in tumor mono-cultures or static conditioned media experiments, suggesting a flow-mediated paracrine signaling mechanism exists with surrounding tumor cells that elicits a change in expression of angiogenic factors. Findings from this work have significant implications regarding low blood velocities commonly seen in the tumor vasculature, suggesting high shear stress-regulation of angiogenic activity is lacking in many vessels, thereby driving tumor angiogenesis.     

Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis

Human angiogenin (ANG), the first member of the angiogenin family (from the pancreatic ribonuclease A superfamily) to be identified, is an angiogenic factor that induces neovascularization. It has received much attention due to its involvement in the growth of tumors and its elevated expression level in pancreatic and several other cancers. Recently the biological role of ANG has been shown to extend to the nervous system. Mutations in ANG have been linked with familial as well as sporadic forms of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by selective destruction of motor neurons. Furthermore, mouse angiogenin-1 has been shown to be expressed in the developing nervous system and during the neuronal differentiation of pluripotent stem cells. We have now characterized the seven variants of ANG reported in ALS patients with respect to the known biochemical properties of ANG and further studied the biological properties of three of these variants. Our results show that the ribonucleolytic activity of six of the seven ANG-ALS implicated variants is significantly reduced or lost and some variants also show altered thermal stability. We report a significant reduction in the cell proliferative and angiogenic activities of the three variants that we chose to investigate further. Our studies on the biochemical and structural features of these ANG variants now form the basis for further investigations to determine their role(s) in ALS.     

血管生成素与炎症性疾病

血管生成素（angiogenin,ANG）是首个被发现来源于肿瘤的具有血管生成能力的蛋白质,但其在炎症中的作用机制尚未完全阐明. 研究表明, ANG在炎症性疾病的发生发展中起重要作用,并与炎症的调控密切相关,而慢性炎症正是导致肿瘤形成、生长和转移的因素之一. 本文以ANG与炎症的关联为基础,结合我们的工作阐述ANG在炎症性疾病特别是肿瘤中的作用和调控机制,明确ANG与蛋白质的相互作用、对信号通路的调控及核内作用是其发挥功能的重要机制,也可能是调控肿瘤炎症的重要机制. 因而,深入研究ANG与炎症的关系不仅可加深我们对ANG兼具抗炎、抗新生血管双重功能的认识,更可为炎症性疾病的治疗提供潜在的作用靶点和新的思路和方法.     

Direct Role of PDGF-BB in Lymphangiogenesis and Lymphatic Metastasis

Genetic instability of tumor cells often leads to amplified expression of multiple growth factors that contribute to angiogenesis and tumor growth. Members of the platelet-derived growth factor (PDGF) family are frequently utilized growth factors by many tumors to support their growth. PDGFs have previously been found to induce tumor growth by directly stimulating cell growth of certain types of tumors. We have recently demonstrated that PDGFs are potent angiogenic factors. Particularly, the angiogenic activity of PDGFs can be potentiated in the presence of other angiogenic factors. In addition to stimulation of blood angiogenesis, we have recently found that PDGFs can directly stimulate lymphangiogenesis and lymphatic metastasis. In this review, multiple roles of PDGFs in control of tumor growth and metastasis are discussed.     

血管生成素与前列腺癌

血管生成素（angiogenin,ANG）属脊椎动物特异的核糖核酸酶A超家族第5个成员,是一种分泌型核糖核酸酶,在人类前列腺癌高表达.ANG在前列腺癌的上皮细胞和内皮细胞转位入核,通过刺激rRNA生物合成而介导肿瘤血管新生、癌细胞存活及增殖,从而促进前列腺癌的进程.ANG刺激rRNA合成不仅为前列腺内皮细胞发生癌变所必需,也是前列腺癌细胞不依赖雄激素生长所必需.动物实验证明,各种针对ANG的拮抗剂,包括抑制其核转位、功能和活性的抑制剂均可抑制前列腺癌.现已明确ANG的作用不依赖雄激素,从而为ANG作为去势（即睾丸切除）抗性前列腺癌（castration resistant prostate cancer）的治疗靶标提供了坚实的理论基础.